Drug Trial Radar · NCT07216443
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Nov 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Orca Biosystems, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) from an 8/8 human leukocyte antigen (HLA)-matched (reduced-intensity conditioning \[RIC\] or nonmyeloablative \[NMA\] cohorts) or 7/8 HLA-mismatched (RIC cohort) donor for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).
Conditions
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Mixed Phenotype Acute Leukemia
Interventions
Orca-TBiological
An allogeneic stem cell and T-cell immunotherapy biologic
Primary outcomes
What the sponsor says the trial is designed to measure.
- 8/8 HLA-Matched RIC Cohort: GVHD-free and relapse-free survival (GRFS)Time frame: Day 0 through day +365 after transplantation
- 8/8 HLA-Matched NMA Cohort: Incidence of neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
- 8/8 HLA-Matched NMA Cohort: Time to neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
- 7/8 HLA-Mismatched RIC Cohort: Incidence of neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
- 7/8 HLA-Mismatched RIC Cohort: Time to neutrophil engraftmentTime frame: Day 0 through day +28 after transplantation
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
UCLA Department of Medicine
Los Angeles, California · Recruiting
Colorado Blood Cancer Institute / St. Luke's Medical Center
Denver, Colorado · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Vanderbilt University, Ingram Cancer Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.